Keros Therapeutics, Inc. · NASDAQ:KROS

Bienaime Jean Jacques received 7,142 Keros Therapeutics, Inc. shares as an award (Form 4)

Traded Jun 3, 2026 · Filed Jun 5, 2026

On Jun 3, 2026, Bienaime Jean Jacques (Director) received 7,142 Keros Therapeutics, Inc. shares as an award, leaving 16,592 shares. Filed Jun 5, 2026 (Form 4).

Awarded
7,142 shares
Holding after
16,592 shares
Trading plan
No
Role
Director

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jun 3, 2026Common StockAward7,14216,592Direct

Source

View original at SEC

Related